/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products.
Clarity establishes a US Center of Excellence for Targeted Copper Theranostics kualalumpurtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kualalumpurtimes.com Daily Mail and Mail on Sunday newspapers.
Clarity establishes a US Center of Excellence for Targeted Copper Theranostics malaysiasun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaysiasun.com Daily Mail and Mail on Sunday newspapers.
SYDNEY, June 28, 2023 /PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center (IAC), a research facility operated by Idaho State University (ISU), for Targeted Copper Theranostics (TCTs). The IAC is a unique research facility operated by ISU located in southeast Idaho, US. It is the result of the Nuclear Science Application Project, providing opportunities for scientists and engineers from the University, the private sector and the national laboratories to utilise specialised nuclear facilities. Clarity is establishing the Center of Excellence at the IAC to advance research and development (R&D) of TCTs close to a source of copper-67 (Cu-67 or 67Cu) production. This investment will enable Clarity to effici